Recce Pharmaceuticals R&D Advance Announcement

Recce Pharmaceuticals Limited (ASX: $RCE) has announced the receipt of AUD $11,178,965 as an R&D Advance with Endpoints Capital, capturing the Company's Research and Development (R&D) tax incentive for FY23/24 & FY25. This non-dilutive funding reflects R&D rebate credits for FY23/24 and future anticipated R&D applicable expenditure for FY25, enabling the Company to leverage its R&D expenditure benefits on a here today basis.

Executive Commentary on R&D Advance

James Graham, Chief Executive Officer of Recce Pharmaceuticals, stated, 'Securing this advanced funding from Endpoints is a testament to the strength of Recce's scientific platform and the potential of our pipeline. This non-dilutive funding not only extends our financial runway but facilitates the acceleration of our multiple clinical programs. We thank Endpoints for having confidence in our vision and look forward to leveraging this partnership to drive meaningful progress in the fight against antimicrobial resistance.'

Summary of R&D Advance and Outlook

Recce Pharmaceuticals has secured a significant R&D advance of AUD $11.17 million with Endpoints Capital, reflecting the Company's ability to capture R&D tax incentives and leverage future R&D expenditure. This non-dilutive funding extends the Company's financial runway and accelerates its multiple clinical programs, demonstrating confidence in Recce's scientific platform and pipeline potential. With the recent Advanced Overseas finding and the 43.5% R&D rebate extension, Recce Pharmaceuticals is well-positioned to drive meaningful progress in combating antimicrobial resistance. The Company's focus on developing a New Class of Synthetic Anti-Infectives to address antibiotic-resistant superbugs and emerging viral pathogens aligns with its ambitions to make a significant impact on global health challenges.